Titan Pharmaceuticals Inc. (OTCQB: TTNP) is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company’s lead product candidate, Probuphine®, is a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment … Continue reading →

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors as well as the bone marrows of some patients … Continue reading →

TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies: TG-1101 and TGR-1202, both of which … Continue reading →

Tecogen Inc. (NASDAQ: TGEN) manufactures, installs and maintains high-efficiency, ultra-clean combined heat and power products – including natural gas engine-drive cogeneration, air conditioning systems and water heaters for residential, commercial and industrial use. For over 20 years, the company has … Continue reading →

TapImmune Inc. (OTCQB: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company’s peptide or nucleic acid-based immunotherapeutics comprise one or more naturally processed epitopes designed to comprehensively … Continue reading →

Stevia First Corp. (OTCQB: STVF) is an agricultural biotechnology company enabling the production of dramatically healthier food and nutrition products. The company has developed and is commercializing a novel bioprocessing technique that has the potential to increase global stevia output … Continue reading →

Stemline Therapeutics, Inc. (NASDAQ: STML) is a clinical stage biopharmaceutical company developing novel oncology therapeutics that primarily target cancer stem cells and tumor bulk. The company’s pipeline currently includes two clinical stage product candidates, SL-401 and SL-701. SL-401 is a … Continue reading →

StemCells, Inc. (NASDAQ: STEM) is currently engaged in the clinical development of its innovative HuCNS-SC® platform technology as a potential treatment for both neurological and retinal disorders. The company’s top-line data from its phase I/II clinical trial in thoracic spinal … Continue reading →

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) is the leading manufacturer of sustainable keyhole limpet hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Through a recently executed strategic collaboration, the company has established itself as the only … Continue reading →

SteadyMed Ltd. (NASDAQ: STDY) is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parental delivery needs. The company’s lead drug product candidate, Trevyent®, utilizes its proprietary PatchPump drug … Continue reading →